Brisk vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (92 vs 44)

Brisk

EmergingConsumer Food & Beverage

Iced Tea

Value-positioned RTD iced tea from PepsiCo-Unilever joint venture; bold flavors at accessible prices in convenience stores competing with AriZona in mainstream tea.

AI VisibilityBeta
Overall Score
C44
Category Rank
#3 of 5
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
44
Gemini
54

About

Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positioned itself as a bold, value-priced iced tea targeting younger consumers who wanted flavorful, refreshing beverages at affordable prices — often sold in large cans and bottles that delivered more volume at lower per-ounce costs than premium tea brands. The brand's irreverent advertising featuring clay-animated celebrities became culturally memorable.

Full profile

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A92
Category Rank
#61 of 1167
AI Consensus
73%
Trend
down
Per Platform
ChatGPT
86
Perplexity
90
Gemini
92

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

44
Overall Score
92
#3
Category Rank
#61
74
AI Consensus
73
stable
Trend
down
52
ChatGPT
86
44
Perplexity
90
54
Gemini
92
55
Claude
98
51
Grok
93

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.